Back
Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications.
Journal article

Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications.

  • Nestelberger T Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Kaiser C Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Jeger R Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • 2020-01-11
Published in:
  • Expert opinion on drug delivery. - 2020
Coronary artery disease
bifurcation lesions
de novo stenosis
drug-coated balloon
drug-eluting balloon
percutaneous coronary intervention
small-vessel disease
Angioplasty, Balloon, Coronary
Animals
Cardiovascular Diseases
Coronary Vessels
Drug Delivery Systems
Humans
English Introduction: Newer-generation drug-eluting stents (DES) are the standard of care for the treatment of symptomatic coronary artery disease. However, their efficacy is limited by in-stent restenosis and stent thrombosis. Drug-coated balloons (DCB) are a treatment option for in-stent-restenosis and for certain clinical and anatomical situations in de novo diseases such as small coronary arteries, bifurcation lesions, and high bleeding risk situations.Areas covered: This review summarizes the current clinical status of DCB angioplasty in coronary artery disease.Expert opinion: DCB deliver an anti-proliferative drug into the vessel wall without implanting a stent and are a promising and technique in the treatment of coronary artery disease. Several studies and meta-analysis have demonstrated the safety and efficacy of DCB angioplasty for several indications such as in-stent restenosis, small-vessel disease, and high bleeding risk. Due to absent short- and long-term complications of stent implantation and a short dual antiplatelet therapy duration, DCB angioplasty has the potential to achieve a clear role in the interventional field in clinical settings with a comparable or even a superior efficacy in comparison with DES use.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/206836
Statistics
Document views: 49 File downloads: